Next Science (ASX:NXS) - Cotización, noticias y análisis

Resumen de acción NXS

NXS fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 25.6%

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

Tiene menos de 1 año de cash runway

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Los accionistas han sido diluidos en el último año

No tiene una capitalización de mercado significativa (A$124M)

Competidores de Next Science Limited

SDI

ASX:SDI

AU$101.0m

Nanosonics

ASX:NAN

AU$851.4m

PolyNovo

ASX:PNV

AU$1.4b

Lumos Diagnostics Holdings

ASX:LDX

AU$25.5m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Next Science
Historical stock prices
Current Share Price	AU$0.35
52 Week High	AU$0.67
52 Week Low	AU$0.18
Beta	1.04
1 Month Change	0%
3 Month Change	9.38%
1 Year Change	-41.67%
3 Year Change	-80.11%
5 Year Change	-84.30%
Change since IPO	-74.07%

Noticias y actualizaciones recientes

Will Next Science (ASX:NXS) Spend Its Cash Wisely?

Apr 16

Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 26% Bounce

Mar 06

Recent updates

Will Next Science (ASX:NXS) Spend Its Cash Wisely?

Apr 16

Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 26% Bounce

Mar 06

Potential Upside For Next Science Limited (ASX:NXS) Not Without Risk

Dec 26

Next Science Limited (ASX:NXS) Analysts Just Trimmed Their Revenue Forecasts By 10%

Oct 26

Take Care Before Jumping Onto Next Science Limited (ASX:NXS) Even Though It's 26% Cheaper

May 13

The Next Science Limited (ASX:NXS) Analysts Have Been Trimming Their Sales Forecasts

Feb 03

Here's Why We're Not Too Worried About Next Science's (ASX:NXS) Cash Burn Situation

Jan 25

What Type Of Returns Would Next Science's(ASX:NXS) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Nov 23

Rentabilidad de los accionistas

	NXS	AU Medical Equipment	Mercado AU
7D	12.9%	-0.2%	0.7%
1Y	-41.7%	15.5%	6.3%

Rentabilidad vs. Industria: NXS obtuvo unos resultados inferiores a los del sector Australian Medical Equipment , que el año pasado arrojó un rendimiento del 14.7%.

Rentabilidad vs. Mercado: NXS obtuvo unos resultados inferiores a los del mercado Australian, que fue del 3.9% el año pasado.

Volatilidad de los precios

Is NXS's price volatile compared to industry and market?
NXS volatility
NXS Average Weekly Movement	12.8%
Medical Equipment Industry Average Movement	10.0%
Market Average Movement	8.9%
10% most volatile stocks in AU Market	17.4%
10% least volatile stocks in AU Market	3.5%

Precio estable de las acciones: El precio de las acciones de NXS ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de NXS (13%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2012	n/a	I.V. Hall	www.nextscience.com

Next Science Limited se dedica a la investigación, desarrollo y comercialización de tecnologías que abordan los problemas de salud humana causados por biopelículas, bacterias incrustantes, hongos, virus e infecciones en Norteamérica, Australia y Nueva Zelanda. Ofrece SURGX, un gel antimicrobiano que se ajusta a la herida postoperatoria; BACTISURE para el lavado de heridas; BlastX, un gel antimicrobiano para heridas que proporciona un tratamiento de heridas manteniendo un entorno húmedo de la herida, lo que favorece la cicatrización de la herida; y XPERIENCE para su uso en la limpieza y eliminación de residuos, incluidos los microorganismos de las heridas. La empresa se fundó en 2012 y tiene su sede en Sídney (Australia).

Resumen de fundamentos de Next Science Limited

¿Cómo se comparan los beneficios e ingresos de Next Science con su capitalización de mercado?
Estadísticas fundamentales de NXS
Capitalización bursátil	AU$102.09m
Beneficios(TTM)	-AU$24.56m
Ingresos (TTM)	AU$33.47m

3.1x

Ratio precio-ventas (PS)

-4.2x

Ratio precio-beneficio (PE)

¿Está NXS sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de NXS
Ingresos	US$22.18m
Coste de los ingresos	US$5.94m
Beneficio bruto	US$16.23m
Otros gastos	US$32.51m
Beneficios	-US$16.27m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.056
Margen bruto	73.20%
Margen de beneficio neto	-73.36%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado NXS a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción NXS

Recompensas

Análisis de riesgos

Competidores de Next Science Limited

ASX:SDI

AU$101.0m

ASX:NAN

AU$851.4m

ASX:PNV

AU$1.4b

ASX:LDX

AU$25.5m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

New minor risk - Share price stability

Next Science Limited to Report Q1, 2024 Results on Apr 24, 2024

Will Next Science (ASX:NXS) Spend Its Cash Wisely?

Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 26% Bounce

Next Science Limited, Annual General Meeting, May 03, 2024

Full year 2023 earnings released: US$0.069 loss per share (vs US$0.06 loss in FY 2022)

Recent updates

New minor risk - Share price stability

Next Science Limited to Report Q1, 2024 Results on Apr 24, 2024

Will Next Science (ASX:NXS) Spend Its Cash Wisely?

Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 26% Bounce

Next Science Limited, Annual General Meeting, May 03, 2024

Full year 2023 earnings released: US$0.069 loss per share (vs US$0.06 loss in FY 2022)

Next Science Limited to Report Fiscal Year 2023 Results on Feb 28, 2024

Potential Upside For Next Science Limited (ASX:NXS) Not Without Risk

Next Science Limited has completed a Follow-on Equity Offering in the amount of AUD 23.800122 million.

Next Science Limited (ASX:NXS) Analysts Just Trimmed Their Revenue Forecasts By 10%

Consensus revenue estimates decrease by 10%

Next Science Limited Announces the Appointment of Katherine Ostin as Independent Non-Executive Director

Consensus revenue estimates increase by 26%, EPS downgraded

New minor risk - Shareholder dilution

First half 2023 earnings released: US$0.04 loss per share (vs US$0.032 loss in 1H 2022)

New minor risk - Financial data availability

Next Science Limited Announces Board Changes

Next Science Limited Appoints Marc Zimmerman as Chief Financial Officer

New minor risk - Share price stability

Next Science Limited Commercialising Its Proprietary Xbiotm Suite of Products

Next Science Limited Announces Executive Changes

Take Care Before Jumping Onto Next Science Limited (ASX:NXS) Even Though It's 26% Cheaper

Founder & CTO recently sold AU$1.5m worth of stock

Consensus EPS estimates fall from profit to US$0.051 loss, revenue upgraded

Full year 2022 earnings released: US$0.06 loss per share (vs US$0.047 loss in FY 2021)

Next Science Limited, Annual General Meeting, May 26, 2023

The Next Science Limited (ASX:NXS) Analysts Have Been Trimming Their Sales Forecasts

Forecast breakeven date pushed back to 2024

Next Science Limited announced that it expects to receive AUD 10 million in funding from Walker Group Holdings Pty Limited

Insufficient new directors

Next Science Limited Announces the Launch of Topical Collagen Products

Next Science Limited Announces Health Canada Given Licensing Approval for XPERIENCE

First half 2022 earnings released: US$0.032 loss per share (vs US$0.021 loss in 1H 2021)

Forecast breakeven date pushed back to 2024

Next Science Limited to Report First Half, 2022 Results on Aug 25, 2022

Consensus forecasts updated

Next Science Limited's Judith Mitchell to Step Down as Chief Executive Officer

Insufficient new directors

MD, CEO & Executive Director recently sold AU$123k worth of stock

Next Science Limited, Annual General Meeting, May 27, 2022

Forecast to breakeven in 2024

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We're Not Too Worried About Next Science's (ASX:NXS) Cash Burn Situation

Insufficient new directors

Founder & CTO recently sold AU$8.6m worth of stock

First half 2021 earnings released: US$0.021 loss per share (vs US$0.037 loss in 1H 2020)

Next Science Limited Agrees to Open Negotiations with Zimmer, Inc

Next Science Limited Provides Revenue Guidance for the First Half of 2021

Next Science Limited Receives Approval for BlastX from Therapeutic Goods Administration for Sale in Australia

Independent Non-Executive Chairman George Savvides has left the company

Next Science’s XPERIENCE No Rinse Antimicrobial Solution Cleared by FDA for Sale in USA

Next Science Limited Announces XPerience No Rinse Antimicrobial Solution Cleared by FDA for Sale in USA

Independent Non-Executive Director recently sold AU$564k worth of stock

MD, CEO & Executive Director exercised options to buy AU$2.5m worth of stock.

Full year 2020 earnings released: US$0.064 loss per share (vs US$0.086 loss in FY 2019)

Next Science Limited (ASX:NXS) Is Expected To Breakeven In The Near Future

Next Science Limited, Annual General Meeting, May 05, 2021

Analysts update estimates

Full year 2020 earnings released: US$0.064 loss per share (vs US$0.086 loss in FY 2019)